## 1AP20'Rec'd 167.770 28 MAR 2616

Sheet 1 of 1

FORM PTO 1449 (modified)	Atty. Docket No. X16348	Dena 373632			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant GRAFF Jeremy Richard				
	Application Date US Nat'l Entry (if applicable)	Group Art Unit			

U.S. PAT	ENT	DOCUMENTS			· .			-
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2</sup> (if known)		ation Date D-YYYY		of Patentee or of Cited Document	Where R or Rele	olumns, Lines clevant Pages vant Figures
•	AA	US						\ppear
	AB	US						
	AC	US	<del></del>	, ·				· · · · · · · · · · · · · · · · · · ·
FOREIG	N.PA	TENT DOCUMENT	<u>rs</u>					
Examiner Initials*	Cite No. 1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4-</sup> Kind Code5 (if known)	Publication Date MM-DD-YYYY	Name of Pa Applicant of Cit		Pages, Columns, Lin Relevant Passages of Figures Appe	r Relevant	т <sup>6</sup>
/B.P./	BA	WO 01/30331-A2	05-03-2001	CAMERON				
/B.P./	BB	WO 02/02116-A2	01-10-2002	TEICHER	et al.		<del></del>	
	BC				,		· ·	
<u> </u>		NON DAT	rent i ited	ATUDE DA	CUME	NITC		
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher,						T <sup>6</sup>
/B.P./	CA	city and/or country where published.  ZHONG ET AL., Modulation of Hypoxia-inducible Factor 1α Expression by the epidermal Growth Factor/Phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP Pathway in Human Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics, Cancer Research, March 15, 2000, 1541-1545, 60						
/B.P./	СВ	ROKHLIN ET AL., Bisindolylmaleimide IX Facilitates Tumor Necrosis Factor Receptor Family-mediated Cell Death and Acts as an Inhibitor of Transcription, The Journal of Biological Chemistry, September 6, 2002, 33213-33219, Vol. 277, No. 36						<del></del> , ·
/B.P./	CC	TANAKA ET AL., Protein Kinase C Promotes Apoptosis in LNCaP Prostate Cancer Cells through Activation of p38 MAPK and Inhibition of the Akt Survival Pathway, The Journal of Biological Chemistry, September 5, 2003, 33753-33762, Vol. 278, No. 36						
	CD				· · · · · · · · · · · · · · · · · · ·			·

Examiner		Date Considered	
	/Benjamin Packard/	01/24/2008	
Signature	/Benjamin Packard/	1 01/24/2000	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.cov">www.uspto.cov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.